Pharming Achieves Landmark Recommendation from NICE for Joenja®
Pharming Group N.V. is thrilled to announce a significant milestone in the journey of Joenja® (leniolisib), now officially recommended by the National Institute for Health and Care Excellence (NICE) for use in England and Wales. This groundbreaking decision confirms Joenja® as the first and only medicine tailored for the treatment of activated phosphoinositide 3-kinase delta (PI3K?) syndrome, commonly referred to as APDS, in both adult and pediatric patients aged 12 years and older.
Understanding Joenja® and its Role in APDS
Joenja® operates as an oral selective PI3K? inhibitor designed to tackle the unique challenges faced by patients suffering from this rare immunodeficiency. The positive recommendation stems from comprehensive data evaluations, notably the Phase III clinical trials that underscored its ability to significantly enhance clinical outcomes for patients with APDS, a condition marked by severe immune dysregulation.
Clinical Trial Insights
The Phase III trials, pivotal to the NICE recommendation, showcased substantial improvements in immune function when patients were administered leniolisib compared to those receiving a placebo. The open-label extension of the study further highlighted that these benefits were not only significant but also persisted over extended treatment periods, indicating the medication’s long-term effectiveness.
Statements from Leaders in the Field
Fabrice Chouraqui, Chief Executive Officer of Pharming, expressed his enthusiasm over the NICE recommendation, asserting that it serves as a profound endorsement of Pharming’s dedication towards enhancing patient care. His acknowledgment of collaboration with regulatory authorities, medical professionals, and patient groups emphasizes their commitment to making Joenja® available for those who most need it.
Experts in clinical immunology have recognized the benefits of leniolisib extensively. For instance, Professor Sinisa Savic from St James’s University Hospital noted that this recommendation represents a crucial advancement for individuals living with APDS, whose lives are often dictated by recurrent infections and immune dysfunction.
Regulatory Approval and Market Availability
The NICE recommendation aligns perfectly with the approval from the U.K. Medicines and Healthcare products Regulatory Authority (MHRA), validating the rigorous evaluation processes that drugs like leniolisib must undergo to reach the market. For UK residents, Joenja® will be accessible through the NHS, with immediate funding facilitated via the Innovative Medicines Fund, ensuring that patients can access this critical treatment without delay.
Impact on Patients and Families
The significance of this treatment option extends beyond mere clinical outcomes; it stands to dramatically enhance quality of life for patients and their families. As Dr. Susan Walsh, CEO at Immunodeficiency UK, pointed out, the introduction of a targeted therapy like leniolisib represents a monumental leap forward. This drug addresses the core issues associated with APDS, potentially transforming lives burdened by this debilitating condition.
What is Activated Phosphoinositide 3-Kinase ? Syndrome (APDS)?
APDS is an exceedingly rare primary immunodeficiency that disrupts the body’s ability to effectively implement immune responses. Characterized by symptoms such as recurrent infections and autoimmunity, APDS has been linked to genetic variants affecting crucial immune cell development and functionality. Unfortunately, due to its complexity and symptom overlap with other conditions, many patients endure a lengthy diagnostic journey, often taking several years to receive appropriate care.
Currently, APDS prevalence is estimated at one to two individuals per million globally, emphasizing the necessity for targeted therapies like Joenja® that can offer hope to affected families.
About Pharming Group N.V.
Based in Leiden, the Netherlands, Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is committed to transforming the lives of individuals with rare diseases through the development and commercialization of innovative medicines. Their active commitment to research and development is evident as they expand their portfolio, ensuring that patients in over 30 markets worldwide receive the breakthrough treatments they deserve.
Frequently Asked Questions
What is Joenja® used for?
Joenja® is used for the treatment of activated phosphoinositide 3-kinase delta (PI3K?) syndrome (APDS) in patients aged 12 and older, focusing on improving immune responses.
Who can benefit from the NICE recommendation?
This recommendation particularly benefits adult and pediatric patients diagnosed with APDS, making Joenja® a more accessible treatment option.
How does leniolisib work?
Leniolisib functions as a selective PI3K? inhibitor, thus improving immune cell development and function, which are often impaired in patients with APDS.
What is the significance of NICE's approval?
The NICE approval facilitates NHS funding for Joenja®, ensuring immediate access for eligible patients and highlighting the efficacy of leniolisib in treating APDS.
Who is Pharming Group N.V.?
Pharming Group N.V. is a biopharmaceutical company specializing in innovative medications for rare diseases, dedicated to improving patient care globally.
